{"id":626238,"date":"2026-03-02T06:15:17","date_gmt":"2026-03-02T06:15:17","guid":{"rendered":"https:\/\/www.europesays.com\/us\/626238\/"},"modified":"2026-03-02T06:15:17","modified_gmt":"2026-03-02T06:15:17","slug":"semaglutide-may-reverse-damage-caused-by-osteoarthritis-study-suggests-sciencealert","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/us\/626238\/","title":{"rendered":"Semaglutide May Reverse Damage Caused by Osteoarthritis, Study Suggests : ScienceAlert"},"content":{"rendered":"

Medical researchers have discovered that semaglutide may reverse the debilitating tissue damage caused by osteoarthritis, the world’s most common form of arthritis<\/a>.<\/p>\n

The drug behind Ozempic and Wegovy is best known for treating type 2 diabetes<\/a> and helping people lose weight. But the new study found semaglutide appears to protect joints in mice through a mechanism that’s not about easing pressure through weight loss.<\/p>\n

Instead, the drug reprograms the metabolism of cells that synthesize and maintain healthy cartilage, allowing them to generate more energy.<\/p>\n

“This work not only highlights the potential off-target effect of semaglutide as an effective drug to treat metabolic osteoarthritis,” the team from China and the US writes in their published paper<\/a>, “but also reveals a weight loss-independent repair mechanism.”<\/p>\n

In addition to mouse experiments, the researchers also conducted a randomized human trial to assess the effects of semaglutide on pain, mobility, and tissue degradation in individuals with osteoarthritis and obesity.<\/p>\n

\"\"Illustrated comparison of a normal knee and a knee with osteoarthritis. (BruceBlaus\/Wikimedia Commons\/CC BY-SA 4.0<\/a>)<\/p>\n

Obesity, metabolic disorders such as diabetes, and inflammation are major contributors to osteoarthritis progression. These conditions can affect just about every tissue in the body, including bone, cartilage, and synovium<\/a> (the lubricating membrane lining the inner surfaces of joints).<\/p>\n

Semaglutide-based drugs like Ozempic and its kin<\/a> work by mimicking glucagon-like peptide 1 (GLP-1), a natural hormone that stimulates insulin release to manage blood sugar levels. This hormone also tells the brain that mealtime has concluded, facilitating an appetite-suppressing effect.<\/p>\n

Therefore, it seems obvious that weight loss eases osteoarthritis by reducing load-bearing forces on the joints. But this isn’t always the case. Existing osteoarthritis therapies are generally palliative. So while they may alleviate the symptoms, they don’t address the underlying cause.<\/p>\n

\"Subscribe<\/a><\/p>\n

But semaglutide appears to affect joint health at a fundamental level. In mice and humans with obesity and osteoarthritis<\/a>, treatment with semaglutide reduced pain and decreased cartilage degeneration. Mice also had fewer bone spurs and less severe lesions in their joint membranes.<\/p>\n

When the researchers compared cartilage from treated and untreated mice, they detected changes in the expression of nearly 8,300 proteins.<\/p>\n

They included a crucial control: a “pair-feeding” group that ate the same amount as the semaglutide-treated mice. Even with comparable weight changes, the pair-feeding group did not receive the same cartilage protection, suggesting a weight-loss-independent effect on the joint itself.<\/p>\n

\"\"Osteoarthritis causes damage to multiple body tissues, leading to pain and loss of mobility. (Wikimedia Commons\/CFCF\/CC BY-SA 4.0<\/a>)<\/p>\n

Yet it seems the most important biological pathway altered by semaglutide is the “GLP-1R-AMPK-PFKFB3 axis,” a cascade of compounds that affects how various cells produce energy.<\/p>\n

By initiating this cascade of enzymes, semaglutide alters the metabolic processes used by chondrocytes<\/a> (cells found in healthy cartilage), making them more efficient and allowing them to survive.<\/p>\n

As the researchers revealed, a process called glycolysis generated most of the energy for chondrocytes<\/a> in osteoarthritis-affected mice.<\/p>\n

Glycolysis doesn’t require oxygen, so it supplies energy quickly during stressful, high-intensity exercise, like the morning sprint to catch the garbage truck. Yet, due to the lack of oxygen, glycolysis produces only two net ATP (energy-providing) molecules per glucose molecule.<\/p>\n

But after semaglutide treatments, a process called oxidative phosphorylation (OXPHOS) became the preferred metabolic pathway for chondrocytes. Unlike glycolysis, OXPHOS uses oxygen and produces much more ATP, up to 36 molecules per glucose molecule.<\/p>\n

\"\"Chondrocytes are cells responsible for synthesizing and maintaining collagen. (Wikimedia Commons\/Robert M. Hunt<\/a>\/Public Domain)<\/p>\n

To see if any of this might translate to humans, the researchers recruited 20 individuals, aged 50-75, with both obesity and osteoarthritis, and randomly divided them into two groups. One group received sodium hyaluronate (HA), a joint-lubricating, especially effective form of hyaluronic acid<\/a>. The other group received both HA and semaglutide.<\/p>\n

At the end of the 24-week treatment period, the HA+semaglutide group experienced lower osteoarthritis pain scores and substantial improvements in knee function. MRI<\/a> analysis also revealed thicker cartilage and recent cartilage growth in the inner joint areas that bear weight and absorb shock from daily movements.<\/p>\n

The findings from this study may impact global healthcare outcomes. Osteoarthritis affects around 600 million people globally<\/a> and is forecast to afflict one billion people by 2050. It’s also increasing among younger, active populations<\/a>, leading to decades of pain and disability.<\/p>\n

The work adds to growing evidence that GLP-1 drugs may have benefits beyond weight loss<\/a>, and it sharpens the search for new osteoarthritis treatments that target metabolism inside the joint.<\/p>\n

Related: Will Exercise Help Your Osteoarthritis? A New Review Has Surprising Findings<\/a><\/strong><\/p>\n

It is also worth keeping expectations in check. Mouse studies do not always translate to long-term human outcomes, and semaglutide use has its own not-so-rosy side effects and concerns<\/a>.<\/p>\n

“The protective effects of semaglutide on the human knee joint should be interpreted with caution and require further validation by clinical trials<\/a>,” the researchers conclude<\/a>.<\/p>\n

This research was published in Cell Metabolism<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"Medical researchers have discovered that semaglutide may reverse the debilitating tissue damage caused by osteoarthritis, the world’s most…\n","protected":false},"author":3,"featured_media":626239,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11],"tags":[210,352,67,132,68],"class_list":{"0":"post-626238","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-health","8":"tag-health","9":"tag-msft-content","10":"tag-united-states","11":"tag-unitedstates","12":"tag-us"},"share_on_mastodon":{"url":"","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/626238","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/comments?post=626238"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/626238\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media\/626239"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media?parent=626238"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/categories?post=626238"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/tags?post=626238"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}